Penumbra has demonstrated solid revenue growth of 14.61% over the last twelve months, and analysts maintain a strong buy consensus recommendation. As Penumbra continues to innovate and expand its ...

Penumbra, Inc.’s PEN robust product portfolio expansion is poised to drive growth in the upcoming quarters. Additionally, the company’s global expansion efforts are thriving. Meanwhile, unfavorable ...

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ...

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, ...